Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2015

View Archived Issues

Almirall describes novel CRAC channel inhibitors

Discovery, structure of AG-221 presented by Agios Pharmaceuticals

Stemcell Technologies licenses research assets from iPS Academia Japan

RedHill Biopharma hires Recipharm to manufacture phase III candidate

Amgen gives details on discovery of AMG-337

MSI Methylation announces last patient treated in phase II trial of ademetionine in MDD

Oncoceutics announces start of expansion phase in first-in-human ONC-201 trial

GSK poised to begin first-in-human trial of GSK-3174998

Janssen Pharmaceutical presents FFAR4 agonists

Edoxaban endorsed by NICE

Advaxis enters into licensing agreement with Knight Therapeutics for Canada

Bayer Schering Pharma discloses BRD4 inhibitors

RespiVert and Topivert Pharma patent anti-inflammatory kinase inhibitors

Tissue Therapies partners with the Queensland University of Technology on research

Incyte divulges KDM1A inhibitors

Principia Biopharma presents FGFR inhibitors

Alvogen to acquire product portfolio from Pfizer for the U.S.

Global trial of palbociclib launched for patients with hormone receptor-positive early breast cancer

Audentes Therapeutics' AT-001 receives orphan drug designation

Syndax and Genentech to conduct phase Ib/II trial combining entinostat and atezolizumab

Novel nanoparticle-based Epstein-Barr virus vaccine elicits potent antibody responses

Valneva updates on 2015 EB66 licensing agreements

Novo Nordisk begins phase IIIa development of oral semaglutide

Daratumumab gains third FDA orphan drug designation

Strategies focused on the HA stem advance universal influenza vaccine development

Allied-Bristol licenses antibody-recruiting molecule technology from Yale

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...